| ROI Name | ∑ In | % In | log ratio | ∑ Out | % Out |
|---|---|---|---|---|---|
| AL(L) | 594 | 85.7% | -6.21 | 8 | 1.8% |
| CA(L) | 38 | 5.5% | 3.46 | 417 | 93.3% |
| LAL(L) | 43 | 6.2% | -inf | 0 | 0.0% |
| CentralBrain-unspecified | 15 | 2.2% | 0.49 | 21 | 4.7% |
| PLP(L) | 3 | 0.4% | -inf | 0 | 0.0% |
| ICL(L) | 0 | 0.0% | inf | 1 | 0.2% |
| upstream partner | # | NT | conns VP3+_vPN | % In | CV |
|---|---|---|---|---|---|
| TRN_VP3a | 3 | ACh | 86 | 17.0% | 1.1 |
| VP3+VP1l_ivPN (L) | 1 | ACh | 80 | 15.8% | 0.0 |
| VP3+VP1l_ivPN (R) | 1 | ACh | 65 | 12.8% | 0.0 |
| VP3+_l2PN (L) | 3 | ACh | 56 | 11.0% | 1.0 |
| v2LN49 (L) | 2 | Glu | 22 | 4.3% | 0.7 |
| lLN2F_a (L) | 2 | unc | 21 | 4.1% | 0.1 |
| v2LN41 (L) | 2 | unc | 19 | 3.7% | 0.6 |
| l2LN20 (L) | 3 | GABA | 17 | 3.4% | 0.4 |
| lLN2R_a (L) | 2 | GABA | 15 | 3.0% | 0.6 |
| VP2_adPN (L) | 1 | ACh | 12 | 2.4% | 0.0 |
| lLN2X11 (L) | 2 | ACh | 12 | 2.4% | 0.0 |
| v2LN4 (R) | 3 | ACh | 10 | 2.0% | 0.6 |
| lLN1_a (L) | 1 | ACh | 9 | 1.8% | 0.0 |
| lLN2X12 (L) | 4 | ACh | 9 | 1.8% | 0.5 |
| v2LN41 (R) | 2 | unc | 8 | 1.6% | 0.8 |
| lLN1_bc (L) | 6 | ACh | 8 | 1.6% | 0.4 |
| lLN2X04 (L) | 1 | ACh | 6 | 1.2% | 0.0 |
| SLP184 (L) | 1 | ACh | 6 | 1.2% | 0.0 |
| CB1048 (L) | 2 | Glu | 5 | 1.0% | 0.6 |
| lLN2T_a (L) | 3 | ACh | 5 | 1.0% | 0.3 |
| OA-VUMa2 (M) | 2 | OA | 4 | 0.8% | 0.5 |
| lLN2P_c (L) | 2 | GABA | 3 | 0.6% | 0.3 |
| lLN2P_a (L) | 1 | GABA | 2 | 0.4% | 0.0 |
| LHAD4a1 (L) | 1 | Glu | 2 | 0.4% | 0.0 |
| lLN2X05 (L) | 1 | ACh | 2 | 0.4% | 0.0 |
| CSD (R) | 1 | 5-HT | 2 | 0.4% | 0.0 |
| AstA1 (R) | 1 | GABA | 2 | 0.4% | 0.0 |
| lLN2F_b (L) | 1 | GABA | 2 | 0.4% | 0.0 |
| KCg-m (L) | 2 | DA | 2 | 0.4% | 0.0 |
| HRN_VP1l | 1 | ACh | 1 | 0.2% | 0.0 |
| VP3+_l2PN (R) | 1 | ACh | 1 | 0.2% | 0.0 |
| M_l2PNm16 (L) | 1 | ACh | 1 | 0.2% | 0.0 |
| CB0656 (L) | 1 | ACh | 1 | 0.2% | 0.0 |
| l2LN22 (L) | 1 | unc | 1 | 0.2% | 0.0 |
| ALON3 (L) | 1 | Glu | 1 | 0.2% | 0.0 |
| v2LN4 (L) | 1 | ACh | 1 | 0.2% | 0.0 |
| M_vPNml76 (L) | 1 | GABA | 1 | 0.2% | 0.0 |
| LoVP73 (L) | 1 | ACh | 1 | 0.2% | 0.0 |
| VP5+VP3_l2PN (L) | 1 | ACh | 1 | 0.2% | 0.0 |
| VP4_vPN (L) | 1 | GABA | 1 | 0.2% | 0.0 |
| lLN2T_b (L) | 1 | ACh | 1 | 0.2% | 0.0 |
| OA-VUMa5 (M) | 1 | OA | 1 | 0.2% | 0.0 |
| VA1v_vPN (L) | 1 | GABA | 1 | 0.2% | 0.0 |
| M_imPNl92 (L) | 1 | ACh | 1 | 0.2% | 0.0 |
| downstream partner | # | NT | conns VP3+_vPN | % Out | CV |
|---|---|---|---|---|---|
| DN1a (L) | 2 | Glu | 165 | 18.4% | 0.1 |
| KCa'b'-ap1 (L) | 9 | DA | 144 | 16.1% | 0.8 |
| SLP184 (L) | 1 | ACh | 91 | 10.2% | 0.0 |
| LHAV3q1 (L) | 1 | ACh | 89 | 9.9% | 0.0 |
| aMe23 (L) | 1 | Glu | 86 | 9.6% | 0.0 |
| VP2_adPN (L) | 1 | ACh | 66 | 7.4% | 0.0 |
| KCg-s2 (L) | 1 | DA | 55 | 6.1% | 0.0 |
| LHPV4c3 (L) | 2 | Glu | 39 | 4.4% | 0.0 |
| SMP421 (L) | 1 | ACh | 36 | 4.0% | 0.0 |
| LHPV4c1_a (L) | 1 | Glu | 20 | 2.2% | 0.0 |
| VP2+_adPN (L) | 1 | ACh | 19 | 2.1% | 0.0 |
| LHPD5a1 (L) | 1 | Glu | 17 | 1.9% | 0.0 |
| LHPV4c1_b (L) | 2 | Glu | 9 | 1.0% | 0.3 |
| LHPV4c2 (L) | 1 | Glu | 8 | 0.9% | 0.0 |
| SLP210 (L) | 1 | ACh | 7 | 0.8% | 0.0 |
| SLP364 (L) | 2 | Glu | 7 | 0.8% | 0.4 |
| KCg-m (L) | 4 | DA | 7 | 0.8% | 0.5 |
| VM6_adPN (L) | 1 | ACh | 5 | 0.6% | 0.0 |
| LHPV5i1 (L) | 1 | ACh | 4 | 0.4% | 0.0 |
| VP3+VP1l_ivPN (L) | 1 | ACh | 2 | 0.2% | 0.0 |
| lLN2P_c (L) | 1 | GABA | 2 | 0.2% | 0.0 |
| PPL202 (L) | 1 | DA | 2 | 0.2% | 0.0 |
| FB6A_b (L) | 1 | Glu | 1 | 0.1% | 0.0 |
| M_lv2PN9t49_a (L) | 1 | GABA | 1 | 0.1% | 0.0 |
| VL1_vPN (L) | 1 | GABA | 1 | 0.1% | 0.0 |
| TRN_VP3a | 1 | ACh | 1 | 0.1% | 0.0 |
| CB0943 (L) | 1 | ACh | 1 | 0.1% | 0.0 |
| KCg-d (L) | 1 | DA | 1 | 0.1% | 0.0 |
| WED181 (L) | 1 | ACh | 1 | 0.1% | 0.0 |
| M_vPNml79 (L) | 1 | GABA | 1 | 0.1% | 0.0 |
| CL359 (L) | 1 | ACh | 1 | 0.1% | 0.0 |
| CB0734 (L) | 1 | ACh | 1 | 0.1% | 0.0 |
| lLN2X04 (L) | 1 | ACh | 1 | 0.1% | 0.0 |
| ALON2 (L) | 1 | ACh | 1 | 0.1% | 0.0 |
| VP3+VP1l_ivPN (R) | 1 | ACh | 1 | 0.1% | 0.0 |
| M_ilPNm90 (L) | 1 | ACh | 1 | 0.1% | 0.0 |
| PVLP093 (L) | 1 | GABA | 1 | 0.1% | 0.0 |
